Showing 131-140 out of 159
Page 14 of 16« First«...1213141516»
Rapid Plasma Kallikrein Inhibition Following Oral KVD900 Is Associated With Early Symptom Relief in Patients With Hereditary AngioedemaDuckworth EJ, Feener EP, Yea CM, Audhya P, Hampton SL, Smith MD
AAAAI 2022
KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study resultsMaetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM
PMID: 35086692
Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM, Maetzel A, Yea CM, Hampton SL, Feener EP
Clinical & Experimental Allergy
Relationship Between PGI-C Scale and Other PROs in KVD900 Trial in Hereditary AngioedemaAudhya P, Williams P, Yea CM
ACAAI 2021
A single on-demand treatment with orally administered KVD900 significantly slows progression and accelerates resolution of attacks in patients with hereditary angioedema (HAE): Results of a phase 2, placebo-controlled, double-blind cross-over trialAygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Cancian M, Hakl R, Kinaciyan T, Magerl M, Martinez-Saguer I, Stobiecki M, Grivcheva-Panovska V, Kiani-Alikhan S, Krcmova I, Bernstein J, Manning M, Stroud C, Hanzlikova J, Li HH, Longhurst HJ, Melamed IR, Young P, Feener E, Iverson M, Maetzel A, Morten RM, Smith MD, Watissée MI, Williams P, Yea CM, Maurer M, Banerji A, and Riedl MA
EAACI 2021
Prevalence of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physiciansRiedl MA, Danese M, Danese S, Ulloa J, and Maetzel A
EAACI 2021
On-demand Oral Treatment With KVD900 for HAE Attacks Achieves Rapid Exposure and Improves Patient OutcomesBernstein JA, Huamin LH, Yea CM, Maetzel A, Audhya P, Williams P, Banerji A, Riedl MA
ACAAI 2021
Current management of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physiciansRiedl MA, Danese M, Danese S, Ulloa J, and Maetzel A
EAACI 2021
Oral plasma kallikrein inhibitor KV998052 improves arterial blood oxygenation in a murine model of acute respiratory distress syndrome (ARDS)Murugesan N, Clermont AC, and Feener EP
EAACI 2021
Selective Factor XIIa inhibitor KV998083 protects mice against captopril induced vascular leakage and cleavage of high molecular weight kininogenClermont AC, Murugesan N, Edwards HJ, Whitney SA, Pethen SJ, Duckworth EJ, Hampton SL, Feener EP
EAACI 2021